Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality

Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality

This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization’s endorsement of polypill...

Full description

Bibliographic Details
Main Authors:	Anubha Agarwal, Mark D. Huffman
Format:	Article
Language:	English
Published:	Ubiquity Press 2024-02-01
Series:	Global Heart
Subjects:	cardiovascular disease polypills world health organization essential medicines
Online Access:	https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1310

Similar Items

Medicinal herbs: Potential polypills in cardiovascular diseases
by: Samaneh Noroozi, et al.
Published: (2021-04-01)

The Concept of the Polypill in the Prevention of Cardiovascular Disease
by: Brandon Wiley, et al.
Published: (2014-04-01)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
by: Apichard Sukonthasarn, et al.
Published: (2021-03-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
by: Siddharth Birla, et al.
Published: (2023-09-01)

Polypill" conception in modern cardiology
by: I E Chazova, et al.
Published: (2018-12-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
by: Omneya A. Kandil, et al.
Published: (2022-04-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
by: J. Masjuan, et al.
Published: (2021-01-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
by: Lilian Grigorian-Shamagian, et al.
Published: (2021-08-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
by: Lopez-Lopez JP, et al.
Published: (2023-09-01)

Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
by: Keisuke Narita, et al.
Published: (2023-11-01)

Polypill therapy and frailty in elderly: Time to stop treating everything
by: Sunil Kumar, et al.
Published: (2021-04-01)

Three-dimensional printing of flexible polypill
by: Yasir Karkar, et al.
Published: (2023-12-01)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
by: Aishwarya Vijay, et al.
Published: (2023-06-01)

Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review
by: Ana Baumgartner, et al.
Published: (2020-02-01)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
by: Cordero A, et al.
Published: (2023-07-01)

Simple, Accurate and Multianalyte Determination of Thirteen Active Pharmaceutical Ingredients in Polypills by HPLC-DAD
by: Barbara Żuromska-Witek, et al.
Published: (2022-12-01)

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
by: Lilian Grigorian-Shamagian, et al.
Published: (2023-08-01)

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial
by: José M. Mostaza, et al.
Published: (2022-12-01)

Application of an LC–MS/MS method for the analysis of amlodipine, valsartan and hydrochlorothiazide in polypill for a bioequivalence study
by: Jaivik V. Shah, et al.
Published: (2017-10-01)

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico
by: Enrique Gómez-Álvarez, et al.
Published: (2020-08-01)

Evaluation of the polypill therapy effectiveness in patients with arterial hypertension and dyslipidemia who underwent COVID-19
by: V.E. Oleynikov, et al.
Published: (2024-03-01)

Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases
by: Ruth Webster, et al.
Published: (2020-08-01)

3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
by: Hellen Windolf, et al.
Published: (2022-04-01)

Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?
by: Z. D. Kobalava, et al.
Published: (2020-11-01)

Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts
by: Bartlett LE, et al.
Published: (2018-05-01)

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
by: Liliana Laranjo, et al.
Published: (2024-01-01)

Polypill for cardiovascular disease prevention.
by: Dalton, A
Published: (2013)

Uso de la polipíldora cardiovascular en la prevención secundaria de la enfermedad cerebrovascular
by: J. Masjuan, et al.
Published: (2021-01-01)

Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality
by: Ezequiel J. Zaidel, et al.
Published: (2020-08-01)

Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
by: Vincenzo Sucato, et al.
Published: (2024-03-01)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
by: Maciej Banach, et al.
Published: (2023-11-01)

RETRACTED ARTICLE:. WAYS TO IMPROVE TREATMENT EFFICIENCY OF PATIENTS WITH HIGH CARDIOVASCULAR RISK
by: G. A. Baryshnikova, et al.
Published: (2015-09-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
by: Mant, J, et al.
Published: (2021)

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)
by: V. V. Kashtalap
Published: (2022-12-01)

Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension
by: Anthony Rodgers, et al.
Published: (2024-02-01)

Preferences of Healthcare Professionals on 3D-Printed Tablets: A Pilot Study
by: Odelia Goh, et al.
Published: (2022-07-01)

CLINICIAN — TREATS, AND PATIENT — BEING TREATED? RECENT VIEW ON THE TREATMENT ADHERENCE IN CORONARY HEART DISEASE SETTING
by: О. Yu. Shaydyuk, et al.
Published: (2017-10-01)

The World Stroke Organization’s Declaration for worldwide primary stroke and dementia prevention
by: Michael Brainin, et al.
Published: (2020-09-01)

La llamada polipill: ¿una solución o un problema?
by: Luz Álvarez, et al.
Published: (2011-12-01)

Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
by: Muhammad Jami Husain, et al.
Published: (2020-05-01)